KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.

Kato K, Shah MA, Enzinger P, Bennouna J, Shen L, Adenis A, Sun JM, Cho BC, Özgüroğlu M, Kojima T, Kostorov V, Hierro C, Zhu Y, McLean LA, Shah S, Doi T

Open source

DOI: 10.2217/fon-2018-0609
Published: 2019 Apr
Container: Future oncology (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.2217/fon-2018-0609,
  title = {KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.},
  author = {Kato K and Shah MA and Enzinger P and Bennouna J and Shen L and Adenis A and Sun JM and Cho BC and Özgüroğlu M and Kojima T and Kostorov V and Hierro C and Zhu Y and McLean LA and Shah S and Doi T},
  year = {2019},
  journal = {Future oncology (London, England)},
  doi = {10.2217/fon-2018-0609},
  url = {https://doi.org/10.2217/fon-2018-0609}
}

RIS

TY  - JOUR
TI  - KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
AU  - Kato K
AU  - Shah MA
AU  - Enzinger P
AU  - Bennouna J
AU  - Shen L
AU  - Adenis A
AU  - Sun JM
AU  - Cho BC
AU  - Özgüroğlu M
AU  - Kojima T
AU  - Kostorov V
AU  - Hierro C
AU  - Zhu Y
AU  - McLean LA
AU  - Shah S
AU  - Doi T
PY  - 2019
JO  - Future oncology (London, England)
DO  - 10.2217/fon-2018-0609
UR  - https://doi.org/10.2217/fon-2018-0609
ER  -

APA

K, K., MA, S., P, E., J, B., L, S., A, A., JM, S., BC, C., M, Ö., T, K., V, K., C, H., Y, Z., LA, M., S, S., & T, D. (2019). KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.. Future oncology (London, England). https://doi.org/10.2217/fon-2018-0609

Source records

pubmed · retrieved 2026-09-25T00:39:07.136Z